Also, a phase II study in patients with metastatic castration-resistant prostate cancer (NCT01812746), was performed with the targeted polymeric nanoparticle BIND014, a docetaxel encapsulated PLGA-PEG NPs targeted to prostate-specific membrane antigen (PSMA). Here, FOLH1 is linked to prostate cancer.